Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Idiopathic Dilated Cardiomyopathy
Conditions
Idiopathic Dilated Cardiomyopathy
Trial Timeline
Sep 1, 2000 → Mar 1, 2009
NCT ID
NCT01798992About Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin is a approved stage product being developed by AstraZeneca for Idiopathic Dilated Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01798992. Target conditions include Idiopathic Dilated Cardiomyopathy.
What happened to similar drugs?
20 of 20 similar drugs in Idiopathic Dilated Cardiomyopathy were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01798992 | Approved | Completed |
Competing Products
20 competing products in Idiopathic Dilated Cardiomyopathy